

OFFICE OF THE SECRETARY OF STATE
SHEMIA FAGAN
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION
STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

NOTICE OF PROPOSED RULEMAKING
INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 855
BOARD OF PHARMACY

FILED
04/16/2021 12:56 PM
ARCHIVES DIVISION
SECRETARY OF STATE

FILING CAPTION: Proactive procedural rule review

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 05/26/2021 4:30 PM

The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@oregon.gov

800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

HEARING(S)

Auxiliary aids for persons with disabilities are available upon advance request. Notify the contact listed above.

DATE: 05/26/2021

TIME: 9:30 AM

OFFICER: Rachel Melvin

ADDRESS: Oregon Board of Pharmacy
800 NE Oregon St., Suite 150
Portland, OR 97232

SPECIAL INSTRUCTIONS:

This hearing meeting will be held via telephonic conference call. To participate, call 1-877-873-8017, participant code 139360#. Email written comment to pharmacy.rulemaking@oregon.gov by 4:30PM on 5/26/2021. Oral comment can be offered at the hearing on the date and time listed above.

NEED FOR THE RULE(S):

The revision to the proposed rules are a result of the board's 2020-2024 Strategic Plan to proactively review and update rules to ensure clarity, transparency and promote patient safety.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

None

FISCAL AND ECONOMIC IMPACT:

There is no fiscal impact as a result of the proposed rule changes.

COST OF COMPLIANCE:

(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).

There are no known economic impacts to the Oregon Board of Pharmacy, small businesses or members of the public.

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Small businesses were not involved in the development of the proposed rule revisions.

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

There is no fiscal impact as a result of the proposed rule changes.

RULES PROPOSED:

855-006-0005, 855-050-0035, 855-050-0045, 855-050-0070

AMEND: 855-006-0005

RULE SUMMARY: By repealing Division 050, the definition of "prescription drug" will need to be retained. Division 006-Definitions will now include the definition of "prescription drug."

CHANGES TO RULE:

855-006-0005

Definitions ¶¶

As used in OAR chapter 855:¶¶

- (1) "Board" means the Oregon Board of Pharmacy unless otherwise specified or required by the context.¶¶
- (2) "Certified Oregon Pharmacy Technician" means a person licensed by the State Board of Pharmacy who assists the pharmacist in the practice of pharmacy pursuant to rules of the Board and has completed the specialized education program pursuant to OAR 855-025-0005. Persons used solely for clerical duties, such as recordkeeping, cashiering, bookkeeping and delivery of medications released by the pharmacist are not considered pharmacy technicians.¶¶
- (3) "Clinical Pharmacy Agreement" means an agreement between a pharmacist or pharmacy and a health care organization or a physician that permits the pharmacist to engage in the practice of clinical pharmacy for the benefit of the patients of the health care organization or physician.¶¶
- (4) "Collaborative Drug Therapy Management" means the participation by a pharmacist in the management of drug therapy pursuant to a written protocol that includes information specific to the dosage, frequency, duration and route of administration of the drug, authorized by a practitioner and initiated upon a prescription order for an individual patient and:¶¶
 - (a) Is agreed to by one pharmacist and one practitioner; or¶¶
 - (b) Is agreed to by one or more pharmacists at a single pharmacy registered by the board and one or more practitioners in a single organized medical group, such as a hospital medical staff, clinic or group practice, including but not limited to organized medical groups using a pharmacy and therapeutics committee.¶¶
- (5) "Compounding" means the preparation, mixing, assembling, packaging, or labeling of a drug or device:¶¶
 - (a) As the result of a practitioner's prescription drug order, or initiative based on the relationship between the practitioner, the pharmacist and the patient, in the course of professional practice; or¶¶

- (b) For the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale or dispensing; or¶
- (c) The preparation of drugs or devices in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns.¶
- (6) "Confidential Information" means any patient information obtained by a pharmacist or pharmacy.¶
- (7) "Consulting Pharmacist" means a pharmacist that provides a consulting service regarding a patient medication, therapy management, drug storage and management, security, education, or any other pharmaceutical service.¶
- (8) The "Container" is the device that holds the drug and that is or may be in direct contact with the drug.¶
- (9) "Dispensing or Dispense" means the preparation and delivery of a prescription drug pursuant to a lawful order of a practitioner in a suitable container appropriately labeled for subsequent administration to or use by a patient or other individual entitled to receive the prescription drug.¶
- (10) "Interpretation and evaluation of prescription orders" means the review of the order for therapeutic and legal correctness. Therapeutic review includes identification of the prescription drug ordered, its applicability and its relationship to the other known medications used by the patient and determination of whether or not the dose and time interval of administration are within accepted limits of safety. The legal review for correctness of the prescription order includes a determination that the order is valid and has not been altered, is not a forgery, is prescribed for a legitimate medical purpose, contains all information required by federal and state law, and is within the practitioner's scope of practice.¶
- (11) "Labeling" means the process of preparing and affixing of a label to any drug container exclusive, however, of the labeling by a manufacturer, packer or distributor of a non-prescription drug or commercially packaged legend drug or device.¶
- (12) "Monitoring of therapeutic response or adverse effect of drug therapy" means the follow up of the therapeutic or adverse effect of medication upon a patient, including direct consultation with the patient or his agent and review of patient records, as to result and side effect, and the analysis of possible interactions with other medications that may be in the medication regimen of the patient. This section shall not be construed to prohibit monitoring by practitioners or their agents.¶
- (13) "Medication Therapy Management (MTM)" means a distinct service or group of services that is intended to optimize therapeutic outcomes for individual patients. Medication Therapy Management services are independent of, but can occur in conjunction with, the provision of a medication product.¶
- (14) "Nationally Certified Exam" means an exam that is approved by the Board which demonstrates successful completion of a Specialized Education Program. The exam must be reliable, psychometrically sound, legally defensible and valid.¶
- (15) "Non-legend drug" means a drug which does not require dispensing by prescription and which is not restricted to use by practitioners only.¶
- (16) "Offering or performing of those acts, services, operations or transactions necessary in the conduct, operation, management and control of pharmacy" means, among other things:¶
- (a) The creation and retention of accurate and complete patient records;¶
 - (b) Assuming authority and responsibility for product selection of drugs and devices;¶
 - (c) Developing and maintaining a safe practice setting for the pharmacist, for pharmacy staff and for the general public;¶
 - (d) Maintaining confidentiality of patient information.¶
- (17) "Oral Counseling" means an oral communication process between a pharmacist and a patient or a patient's agent in which the pharmacist obtains information from the patient (or agent) and the patient's pharmacy records, assesses that information and provides the patient (or agent) with professional advice regarding the safe and effective use of the prescription drug for the purpose of assuring therapeutic appropriateness.¶
- (18) Participation in Drug Selection and Drug Utilization Review:¶
- (a) "Participation in drug selection" means the consultation with the practitioner in the selection of the best possible drug for a particular patient.¶
 - (b) "Drug utilization review" means evaluating prescription drug order in light of the information currently

provided to the pharmacist by the patient or the patient's agent and in light of the information contained in the patient's record for the purpose of promoting therapeutic appropriateness by identifying potential problems and consulting with the prescriber, when appropriate. Problems subject to identification during drug utilization review include, but are not limited to:¶

(A) Over-utilization or under-utilization;¶

(B) Therapeutic duplication;¶

(C) Drug-disease contraindications;¶

(D) Drug-drug interactions;¶

(E) Incorrect drug dosage;¶

(F) Incorrect duration of treatment;¶

(G) Drug-allergy interactions; and¶

(H) Clinical drug abuse or misuse.¶

(19) "Pharmaceutical Care" means the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life. These outcomes include:¶

(a) Cure of a disease;¶

(b) Elimination or reduction of a patient's symptomatology;¶

(c) Arrest or slowing of a disease process; or¶

(d) Prevention of a disease or symptomatology.¶

(20) "Pharmacy Technician" means a person licensed by the State Board of Pharmacy who assists the pharmacist in the practice of pharmacy pursuant to rules of the Board but has not completed the specialized education program pursuant to OAR 855-025-0012.¶

(21) "Practice of clinical pharmacy" means:¶

(a) The health science discipline in which, in conjunction with the patient's other practitioners, a pharmacist provides patient care to optimize medication therapy and to promote disease prevention and the patient's health and wellness;¶

(b) The provision of patient care services, including but not limited to post-diagnostic disease state management services; and¶

(c) The practice of pharmacy by a pharmacist pursuant to a clinical pharmacy agreement.¶

(22) "Practice of pharmacy" is as defined in ORS 689.005.¶

(23) "Prescription drug" or "legend drug" is as defined in ORS 689.005 and:¶

(a) Required by federal law, prior to being dispensed or delivered, to be labeled with "Rx only"; or¶

(b) Required by any applicable federal or state law or regulation to be dispensed on prescription only or is restricted to use by practitioners only.¶

(24) "Prescription released by the pharmacist" means, a prescription which has been reviewed by the pharmacist that does not require further pharmacist intervention such as reconstitution or counseling.¶

(245) "Prohibited conduct" means conduct by a licensee that:¶

(a) Constitutes a criminal act against a patient or client; or¶

(b) Constitutes a criminal act that creates a risk of harm to a patient or client.¶

(256) "Proper and safe storage of drugs and devices and maintenance of proper records therefore" means housing drugs and devices under conditions and circumstances that:¶

(a) Assure retention of their purity and potency;¶

(b) Avoid confusion due to similarity of appearance, packaging, labeling or for any other reason;¶

(c) Assure security and minimize the risk of their loss through accident or theft;¶

(d) Accurately account for and record their receipt, retention, dispensing, distribution or destruction;¶

(e) Protect the health, safety and welfare of the pharmacist, pharmacy staff and the general public from harmful exposure to hazardous substances.¶

(267) "Quality Assurance Plan" is a written set of procedures to ensure that a pharmacy has a planned and systematic process for the monitoring and evaluation of the quality and appropriateness of pharmacy services and for identifying and resolving problems.¶

(278) "Responsibility for advising, when necessary or when regulated, of therapeutic values, content, hazards and use of drugs and devices" means advice directly to the patient, either verbally or in writing as required by these rules or federal regulation, of the possible therapeutic response to the medication, the names of the chemicals in the medication, the possible side effects of major importance, and the methods of use or administration of a medication.¶¶

(289) "Specialized Education Program" means;¶¶

(a) A program providing education for persons desiring licensure as pharmacy technicians that is approved by the board and offered by an accredited college or university that grants a two-year degree upon successful completion of the program; or¶¶

(b) A structured program approved by the board and designed to educate pharmacy technicians in one or more specific issues of patient health and safety that is offered by:¶¶

(A) An organization recognized by the board as representing pharmacists or pharmacy technicians;¶¶

(B) An employer recognized by the board as representing pharmacists or pharmacy technicians; or¶¶

(C) A trade association recognized by the board as representing pharmacies.¶¶

(2930) "Supervision by a pharmacist" means being stationed within the same work area as the pharmacy technician or certified Oregon pharmacy technician being supervised, coupled with the ability to control and be responsible for the pharmacy technician or certified Oregon pharmacy technician's action. During the declared public health emergency timeframe related to the 2020 COVID-19 pandemic, "supervision by a pharmacist" means pharmacist monitoring of a pharmacy technician or intern being supervised, coupled with the ability to control and be responsible for the technician or interns actions and for the following remote processing functions only: prescription or order entry, other data entry, and insurance processing of prescriptions and medication orders. ¶¶

(301) "Therapeutic substitution" means the act of dispensing a drug product with a different chemical structure for the drug product prescribed under circumstances where the prescriber has not given clear and conscious direction for substitution of the particular drug for the one which may later be ordered.¶¶

(312) "Verification" means the confirmation by the pharmacist of the correctness, exactness, accuracy and completeness of the acts, tasks, or functions performed by an intern or a pharmacy technician or a certified Oregon pharmacy technician.

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.151, ORS 689.155

REPEAL: 855-050-0035

RULE SUMMARY: Division 050 is no longer relevant for current pharmacy practice.

CHANGES TO RULE:

~~855-050-0035~~

~~Over-the-Counter Drug Restrictions~~

~~(1) The following items shall be sold only by or under the direct supervision of a licensed pharmacist in registered pharmacies. They need not bear the store name and address, if in original container, need not be registered, but must be properly labeled. They shall not be available by self-service, but stored in or immediately adjacent to the prescription department. Items bearing prescription legend are excepted and may be sold only on prescription:¶¶~~

~~(a) Ammoniated Mercury ointment, five percent;¶¶~~

~~(b) Sulfa drugs – Alone or in combination;¶¶~~

~~(c) Blue Ointment.¶¶~~

~~(2) The following items shall be sold only by a licensed pharmacist(s) in registered pharmacies, must bear the store name and address, must be properly labeled with adequate warning, must be registered in Official Poison Register, and the purchaser must provide acceptable identification, providing the preparations do not bear prescription legend, in which case they may be sold only on prescription:¶¶~~

~~(a) Arsenic and its preparations;¶¶~~

~~(b) Corrosive sublimate;¶¶~~

~~(c) Cyanides and preparations, including hydrocyanic acid;¶¶~~

~~(d) Hydrochloric acid and any preparation containing free or chemically unneutralized hydrochloric acid (HCl) in a concentration of ten percent or more;¶¶~~

~~(e) Nitric acid or any preparation containing free or chemically unneutralized nitric acid (HNO₃) in a concentration of five percent or more;¶¶~~

~~(f) Sulphuric acid and any preparation containing free or chemically unneutralized sulphuric acid (H₂SO₄) in a concentration of ten percent or more;¶¶~~

~~(g) Solution of ammonia, U.S.P. 28 percent;¶¶~~

~~(h) Carbolic acid.~~

~~Statutory/Other Authority: ORS 689~~

~~Statutes/Other Implemented:~~

REPEAL: 855-050-0045

RULE SUMMARY: Division 050 is no longer relevant for current pharmacy practice.

CHANGES TO RULE:

~~855-050-0045~~

~~Organic Silver Salts~~

~~(1) May be sold only by licensed pharmacists in registered pharmacies.¶~~

~~(2) Solutions must be freshly prepared, unless stabilized.¶~~

~~(3) Must be adequately labeled, to include name and address of store, date of preparation, and percentage content.~~

~~Statutory/Other Authority: ORS 689~~

~~Statutes/Other Implemented:~~

REPEAL: 855-050-0070

RULE SUMMARY: Division 050 is no longer relevant for current pharmacy practice.

CHANGES TO RULE:

~~855-050-0070~~

~~Prescription Drugs~~

~~(1) The following are prescription drugs:¶¶~~

~~(a) Drugs required by federal law to be labeled with either of the following statements:¶¶~~

~~(A) "Caution: Federal law prohibits dispensing without prescription"¶¶~~

~~(B) "Caution: Federal law restricts this drug to be used by or on the order of a licensed veterinarian"; or¶¶~~

~~(C) "Rx only"¶¶~~

~~(b) Drugs designated as prescription drugs by the Oregon Board of Pharmacy¶¶~~

~~(2) The Oregon Board of Pharmacy designates the following drugs as prescription drugs:¶¶~~

~~(a) Preparations containing codeine or salts of codeine¶¶~~

~~(b) Preparations containing opium/paregoric¶¶~~

~~(3) No person shall sell, give away, barter, transfer, purchase, receive or possess prescription drugs except upon the prescription of a practitioner.¶¶~~

~~(4) The following are exempt from the prohibition of section (3) of this rule:¶¶~~

~~(a) Manufacturers¶¶~~

~~(b) Wholesalers;¶¶~~

~~(c) Institutional and retail drug outlets;¶¶~~

~~(d) Practitioners.¶¶~~

~~(5) Individuals who purchase, receive, or possess a prescription drug for the purpose of administration or delivery to a patient are exempt from the prohibition against purchasing, receiving, or possessing prescription drugs contained in section (3) of this rule and ORS 689.765(6).~~

~~Statutory/Other Authority: ORS 689.205~~

~~Statutes/Other Implemented: ORS 689.155, 689.765~~